

1 This document is the Submitted Manuscript version of a Published article that appeared  
2 in its final form in the *International Journal of Pharmaceutics*, copyright ELSEVIER.  
3 To access the final edited and published work see: <https://doi.org/10.1016/j.ijpharm.2022.122482>  
4

5 **Micelle-core/chitosan-shell (chito-micelles) enriched with gamma oryzanol:**  
6 **physical-chemical features, safety, translational nephroprotective potential and emphasis**  
7 **on sirtuin-1 associated machinerics**

8  
9 *Enas Elmowafy<sup>1</sup>, Marwa Omar El-Derany<sup>2</sup>, Luca Casettari<sup>3</sup>, Mahmoud E. Soliman<sup>1,4\*</sup> and Riham*  
10 *I. El-Gogary<sup>1</sup>*

11  
12 *<sup>1</sup>Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain*  
13 *Shams University, Cairo, Egypt,*  
14 *Monazzamet Elwehda Elafrikeya Street, Abbaseyya, Cairo, Egypt, 11566*

15 *<sup>2</sup>Department of Biochemistry, Faculty of Pharmacy, AinShams University, Cairo, Egypt,*  
16 *Monazzamet Elwehda Elafrikeya Street, Abbaseyya, Cairo, Egypt, 11566*

17 *<sup>3</sup>Department of Biomolecular Sciences, University of Urbino Carlo Bo, Piazza delRinascimento,*  
18 *6, 61029 Urbino (PU), Italy.*

19 *<sup>4</sup>Egypt-Japan University of Science and Technology (EJUST), New Borg El Arab, Alexandria*  
20 *21934, Egypt*

21  
22  
23  
24  
25 **\* Corresponding author:**

26 *Mahmoud E. Soliman*

27 Department of Pharmaceutics and Industrial Pharmacy,  
28 Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt  
29 Tel.: +2 01005164052 Fax: +20 2 0224011507.

30 Email: mahmoud.e.soliman@pharma.asu.edu.eg

31

32 **Abstract**

33 Gamma oryzanol (ORZ) is a nutraceutical that is poorly water soluble with poor intestinal  
34 absorption. In the current work, ORZ was nanoformulated into uncoated and chitosan coated  
35 micelles based on methoxy-poly(ethylene glycol)-b-poly( $\epsilon$ -caprolactone) (mPEG-PCL) and  
36 poly( $\epsilon$ -caprolactone)-b-methoxy-poly(ethylene glycol)-b-poly( $\epsilon$ -caprolactone) (PCL-PEG-PCL)  
37 copolymers for augmenting ORZ oral delivery. The physicochemical properties, morphological  
38 study, in-vitro release and safety of the nanoplaforms were determined. Importantly, the  
39 nephroprotective competence of the nanoplaforms was analyzed against acute kidney injury  
40 (AKI) rat model and the sirtuin-1 associated machineries were assessed. The results revealed that  
41 the micelles exerted particle size (PS) from 97.9 to 117.8 nm that was markedly increased after  
42 chitosan coating. The reversal of zeta potential from negative to highly positive further confirmed  
43 efficient coating. *In vitro* release profiles demonstrated prolonged release pattern which followed  
44 Higushi model. The nanoforms conferred higher cell viability values than free ORZ on vero cell  
45 line. The designed micelles displayed augmented nephroprotection compared to free ORZ with  
46 the supremacy of chitosan coated micelles over uncoated ones in restoring kidney parameters to  
47 normal levels. The attenuated AKI was fulfilled via the modulation of sirtuin-1 signaling  
48 pathways translated by restoring the histological features, increasing renal antioxidant states,  
49 renal autophagy and decreasing renal inflammation and renal apoptosis. These outcomes  
50 confirmed that surface modification with chitosan had a considerable leverage on micelles  
51 safety, release behavior and in vivo performance.

52 **Keywords**

53 Oral delivery; gamma oryzanol; polymeric micelles; chitosan; nephroprotection; sirtuin-1

54

55

56

57

## 58 1. Introduction

59 In recent years, the occurrence of nephrotoxicity associated with unrationalized extensive dosing  
60 of some drugs or as an adverse toxic effect of various drugs like antibiotics, anticancers and  
61 other chemicals like pesticides has increased extensively. Moreover, kidney exposure to  
62 chemicals such as glycerol or adenine leads to nephrotoxicity (Adedapo et al., 2021; Al-Okbi et  
63 al., 2019; Azab et al., 2017; Song et al., 2021; Wu and Huang, 2018). The pathogenesis of  
64 kidney failure following exposure to these causative agents, especially glycerol, usually involves  
65 increased serum levels of urea, creatinine and blood urea nitrogen. Moreover, a decrease in renal  
66 blood flow in addition to liberation of myoglobin from muscles into the blood stream occurs  
67 resulting in the production of reactive oxygen species (ROS), lipid peroxidation and acute  
68 tubular necrosis (ACT) which contributes further to inflammatory process, fibrosis and apoptosis  
69 consequently resulting in alteration and loss of renal function and further complications such as  
70 diabetes and stroke. Sirtuin-1 is known to play a central protective role against AKI. Sirtuin-1  
71 has been proved to inhibit cell apoptosis induced by oxidative stress and inflammation.  
72 Interestingly, sirtuin-1 was found to be an important regulator of renal cell autophagy. Whereas,  
73 reduced sirtuin-1 levels were proved to be crucial in the aging of the kidneys through the  
74 deacetylation and the activation of some transcription factors which subsequently reduce ATG-  
75 mediated autophagy. It has been proposed that convalescence from kidney dysfunction can be  
76 achieved through prophylactic and/or early therapeutic administration of antioxidant and / or  
77 anti-inflammatory drugs. Among the powerful candidates proposed for this aim are the  
78 nutraceuticals owing to their reported antioxidant, anti-inflammatory and lipid lowering  
79 effects (Adedapo et al., 2021; Al-Okbi et al., 2019; Song et al., 2021).

80 Gamma oryzanol (ORZ) is a major component isolated from rice bran. Several studies reported  
81 its several beneficial therapeutic activities. It is reported to have powerful antioxidant,  
82 anticancer, anti-inflammatory, lipid lowering and neuroprotective effects owing to its transferulic  
83 acid esters components which accounts for 80% of its composition (Al-Okbi et al., 2019; Rawal  
84 et al., 2018; Ruktanonchai et al., 2009; Viriyaroj et al., 2009; Yang and Chiang, 2019).

85 Recent attention was directed toward investigating the protective effects of gamma ORZ against  
86 multiple kidney diseases. **Al-Okbi et al., 2020** proved the protective effect of ORZ on the kidney  
87 and liver against CVD and hepatocellular carcinoma (Al-Okbi et al., 2019). However, the  
88 underlined molecular mechanism for the therapeutic effects of ORZ in acute kidney injury is still

89 far from clear and the effect of ORZ on sirtuin-1 signaling pathway hasn't been yet discovered.  
90 But unfortunately, the clinical application of ORZ is hampered by its low water solubility, poor  
91 bioavailability and rapid metabolism. To overcome ORZ solubility and stability problems,  
92 several studies formulated ORZ in various nanoforms such as; liposomes, niosomes, solid lipid  
93 nanoparticles, ethylcellulose polymeric nanoparticles, penetration enhancer vesicles (PEVs),  
94 self-emulsifying alginate beads & chitosan nanoparticles (Aldalaen et al., 2020; Ghaderi et al.,  
95 2014; Manosroi et al., 2012; Rawal et al., 2018; Seetapan et al., 2010; Viriyaroj et al., 2009;  
96 Yang and Chiang, 2019). Furthermore, ORZ encapsulation in a nanosystem would exploit from  
97 the diverse advantages of nanodelivery systems such as enhancing better delivery of the drug to  
98 target site(Rawal et al., 2018).

99 Among the most promising nanocarriers emerging are the polymeric micelles. Their amphiphilic  
100 core-shell structure confers the encapsulation of hydrophobic drugs in their cores besides the  
101 hydrophilic stabilizing parts forming the shell eventuating a robust platform that could enhance  
102 drug solubility and targetability hence its therapeutic action. Moreover, the hydrophilic shell has  
103 been reported to minimize protein adsorption on micelles hence eluding the uptake by the  
104 reticuloendothelial system (RES) hence enhancing the drug's bioavailability(Aboud et al., 2020;  
105 Ahmad et al., 2014; Gong et al., 2010; Hou et al., 2019; Zhang et al., 2018). Previously our  
106 group reported the formulation of the hydrophobic drug, methizolamide into diblock copolymer;  
107 mPEG-PCL micelles which showed enhancement in its therapeutic efficacy(Elmowafy et al.,  
108 2019).

109 Further extension to this work, herein we utilized DB and TB copolymers self-organized into  
110 micelles for maneuvering biopharmaceutical performance of the poorly water-  
111 solublenutraceutical ORZ. Intestingly, some studies reported that further coating of nanocarriers  
112 with polymers such as Eudragit® RS 100 or CS could enhance their biocompatibility,  
113 bioadhesivity and stability(Cheng et al., 2019). Therefore, a complimentary approach of  
114 decorating the micelles with a highly biocompatible polymer such as chitosan (CS), has been  
115 attempted. This would probably enhance the biocompatibility, increase the stability,  
116 mucoadhesivity of the nanosystem(Rawal et al., 2018). Furthermore, the incorporation of CS in  
117 the nanosystem has been reported to augment epithelial permeability through enhancing contact  
118 with cell membrane and opening occlusion areas (de C Coelho Junior et al., 2021).

119 To the best of our knowledge, the formulation of ORZ in polymeric copolymeric micelles with  
120 or without CS coating and its in-vitro and in-vivo evaluation for nephroprotection against  
121 glycerol induced AKI hasn't been attempted in any other study so far. Therefore, in this light, the  
122 aim of the present study was to optimize the formulation parameters of polymeric micelles of  
123 ORZ including colloidal size, reasonable entrapment, sustained release pattern, and a promising  
124 safety profile. A comparative study was performed between di-block and tri-block PCL polymers  
125 with respect to their effect on physicochemical attributes of micelles, drug release and solid state  
126 analyses. The effect of micelles coating with CS on the physicochemical properties of the micelles  
127 was studied. In addition, the prophylactic potential of the prepared systems on the in-vivo  
128 glycerol induced AKI in rat and sirtuin-1 associated machineries were studied.

## 129 **2. Materials and Methods**

### 130 **2.1 Materials**

131 mPEG-PCL di-block and tri-block copolymers with respective molecular weight ( $M_w$ ) of 4000  
132 and 5000 Da were synthesized in our lab using methoxy-PEG (mPEG) 1.9 kDa and  $\epsilon$ -  
133 caprolactone, purchased from Polysciences (Germany) and Sigma-Aldrich (Italy), respectively.  
134 Oryzanol (ORZ) was purchased from Bulkactives company, Taiwan. Chitosan (CS), viscosity 9  
135 cP was kindly supplied by Primex, Iceland. Sodium hydroxide, potassium dihydrogen phosphate,  
136 tween 80, chloroform and methanol were supplied from El-Nasr Pharmaceutical Co.,  
137 (Egypt). Vero cells (ATCC® CCL-81™) were obtained from American Type Culture Collection,  
138 (Manassas, VA, USA). Porcine mucin type II, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-  
139 tetrazolium bromide) and DPPH were purchased from Sigma-Aldrich Co. (St Louis, MO, USA).  
140 Spectra/Pore dialysis membrane (molecular weight cutoff 12–14 kDa) was purchased from  
141 Spectrum Laboratories (Canada).

142

### 143 **2.2 Synthesis and characterization of the copolymers.**

144 Synthesis and characterization of mPEG-PCL and PCL-mPEG-PCL were performed by the ring  
145 opening polymerization (ROP) technique and  $^1\text{H-NMR}$  and GPC analysis respectively as  
146 previously described by our group (Elmowafy et al., 2019; Shalaby et al., 2016; Shalaby et al.,  
147 2014).

148

### 149 **2.3 Preparation of micelle-core**

150 ORZloaded micelle-core was prepared using a modified thin film hydration method as stated  
151 previously (Elmowafy et al., 2019). In brief, pegylated PCL copolymer was weighed into a round  
152 bottom flask and dissolved in chloroform:methanol mixture (3:2 v/v) with the aid of sonication  
153 at 25°C. Subsequently, ORZ was dissolved in the copolymer solution, at polymer to drug ratios  
154 of 5:1 and 10:1 w/w. The organic solvents were removed using a rotary evaporator (HB4-basic,  
155 IKA, Germany) under the following conditions: rotation speed 200 rpm, rotation time 30 min  
156 and temperature 60°C till the formation of a thin film of dry drug-polymer mixture. Hydration of  
157 the obtained film was performed through the addition of Milli-Q water (10 mL) followed by  
158 rotation for an additional 30 min. The micelles were filtrated using a 0.2 µm cellulose acetate  
159 membrane filter to remove the unincorporated drug aggregates (Patra et al., 2018). The  
160 formulations were sealed in clean glass vials and stored under cool conditions at 4°C. The  
161 composition of the ORZ micelle-core is presented in **Table 1**.

162

#### 163 **2.4. Dimensional characterization**

164 Colloidal parameters (micelle size (MS), polydispersity index (PDI) and zeta potential (ZP))  
165 were measured at 25°C by diluting micelles with deionized water using a  
166 Zetasizer (Zetasizer; Malvern Instruments, Malvern, UK).

167

#### 168 **2.5. Determination of ORZ percentage entrapment efficiency (EE%) and percentage drug 169 loading (DL%)**

170 The quantity of ORZ encapsulated within the micelle-core was determined after filtration of the  
171 micelles using 0.22 µm filters to remove the unentrapped drug. The percentage entrapment  
172 efficiency (% EE) of ORZ was estimated as previously reported (Aldalaen et al., 2020). The  
173 amount of ORZ entrapped in the micelles was calculated after micelles disruption by methanol,  
174 in which 100 µL of micelles were mixed with 10 ml of methanol. The drug was measured  
175 spectrophotometrically at 319 nm using a UV-Visspectrophotometer (Shimadzu, model UV-  
176 1601 PC, Kyoto, Japan). The amount of ORZ was then determined according to a calibration  
177 curve of ORZ in methanol.

178 The % EE and % DL of ORZ were estimated using the following equations (Kumar et al., 2020):

$$179 \text{ EE\%} = \frac{\text{Weight of loaded ORZ in micelles}}{\text{Theoretical Weight of ORZ added}} \times 100 \quad (1)$$

180 
$$DL\% = \frac{\text{Weight of loaded ORZ in micelles}}{\text{Weight of copolymer}} \times 100 \quad (2)$$

181 **2.6. Preparation and characterization of micelle-core/ chitosan shell nano-carriers (chito-**  
182 **micelles)**

183 The selected micelle-core formulations were coated using different concentrations of CS solution  
184 (1% acetic acid), namely 0.25, 0.5 and 1% w/v. In brief, an aqueous solution of CS was added to  
185 the formed micellardispersion to achieve a micelles: CS coat ratio of 1:1 v/v, and stirred for 30  
186 min at room temperature. The MS, PDI and ZP of the formed chito-micelles were measured  
187 using a Zetasizer.

188

189 **2.7. Morphological examination**

190 Morphological examination of the selected micelle-core and chito-micelles was done using a  
191 high-resolution transmission electron microscope (HR-TEM)(Jeol Electron Microscope, JEM-  
192 1010, Japan). A droplet of the suspension was added to a carbon film-covered copper grid  
193 without staining. Excess liquid was drained with the aid of a filter paper. After sample dryness,  
194 PMs were visualized under an electron beam at a voltage of 200 kV.

195

196 **2.8. *In vitro* release characteristics and kinetics in simulated intestinal fluid (SIF)**

197 The extent of ORZ release from the selected micelle-core, chito-micelles and  
198 ORZethanolic solution was carried out using a membrane diffusion technique (El-Gogary et al.,  
199 2022; Elmowafy et al., 2020; Elmowafy et al., 2019). An aliquot of the selected formulations or  
200 drug solution equivalent to 1 mg of ORZ was placed in the dialysis membrane. The dialysis bag  
201 was then immersed in vials containing 100 mL of the dissolution medium (simulated intestinal  
202 fluid (SIF) containing 0.5% w/v tween 80; pH 6.8) maintained at 37 °C in a shaking incubator at  
203 50 rpm. At predetermined time points over a 24 h period, 1 mL aliquots were withdrawn and the  
204 same volume of fresh SIF was added back to the vials. ORZ concentration was determined by UV  
205 spectrophotometry (UV-1601 PC, Shimadzu, Kyoto, Japan) at 319 nm. Kinetics of  
206 drug release were studied by plotting data obtained from *in vitro* release  
207 in various kinetic models viz. first order, zero order, and Higuchi. Mechanism of drug release  
208 was assessed by Peppas model.

209 **2.9. Solid state characterization**

### 210 **2.9.1. Differential scanning calorimetry (DSC)**

211 The thermal properties of ORZ, DB and TB mPEG-PCL copolymer, selected lyophilized  
212 micelle-core formulations and their corresponding chito-micelles “freeze dried using Christ,  
213 alpha 1-2 LD plus, Germany), were studied using DSC (Shimadzu-DSC 60, Japan). Powdered  
214 samples (2-3 mg) were sealed in aluminum pans with lids and scanned at a temperature between  
215 0 and 300°C at a rate of 10°C/min, using dry nitrogen as a carrier gas with a flow rate of 25  
216 mL/min (Gad et al., 2022; Lamie et al., 2022).

217

### 218 **2.9.2. FT-IR characterization**

219 FT-IR spectra of ORZ, DB and TBmPEG-PCL copolymer, selected lyophilized micelle-core  
220 formulations and their corresponding chito-micelles were recorded in the range of 4000-400 cm<sup>-1</sup>  
221 on a Nicolet 6700 FTIR (Thermo Scientific, USA). Powdered samples were loaded on KBr discs  
222 without special treatment. All spectra were recorded at a resolution of 4 cm<sup>-1</sup> and 16 scans at  
223 ambient temperature.

### 224 **2.10. Colloidal stability study**

225 The colloidal stability of the selected chito-micelles was tracked over time using assessments of  
226 physical parameters (PS, PDI, and ZP). The stability experiments were continued for a period of  
227 30 days, during which the micelles were stored in the refrigerator at 4°C.

228

### 229 **2.11. Suitability of chito-micelles for oral delivery**

#### 230 **2.11.1. Stability of chito-micelles in simulated intestinal fluid (SIF)**

231 The physical stability of the selected chito-micelles was evaluated in intestinal conditions as  
232 reported earlier (Kumar et al., 2020). The chito-micelles were added into SIF and incubated for 6  
233 h at 37 °C (Ji et al., 2018). Subsequent to incubation, chito-micelles were collected and measured  
234 for their PS and PDI by using a zeta-sizer.

#### 235 **2.11.2. Mucoadhesion**

236 The *in vitro* mucin assay was conducted to investigate the interaction  
237 between mucin and the prepared chito-micelles as described previously with slight modification  
238 (Kengkittipat et al., 2021). Briefly, porcine mucin was dissolved in SIF (0.1% w/v). The mucin  
239 solution was then centrifuged at 4000 rpm for 20 min. Then the mucin solution was added to



240 chito-micelles and uncoated micelles at 1:1 v/v ratio and incubated at 37 °C for 1 h. MS and  
241 ZP were assessed by using dynamic light scattering. For comparison, the corresponding micelle-  
242 core was also investigated under the same condition.

### 243 2.12. Comparative *In vitro* antioxidant potential

244 DPPH free radical scavenging assay was conducted in order to elucidate the antioxidant activity  
245 of the encapsulated ORZ in the selected chito-micelles (C-M<sub>3(0.5)</sub>) and the corresponding  
246 micelle-core (M<sub>3</sub>) as previously described (Aslam et al., 2020). The freshly prepared DPPH  
247 solution (0.1 mM) was added to the selected formulations (500 µg/mL) separately and incubated  
248 for half an hour at room temperature. The absorbance of the solution was then determined at 517  
249 nm and % inhibition of DPPH was measured. Ascorbic acid was used as a standard antioxidant.

### 250 2.13. *In vitro* cytocompatibility

251 In order to assess the nephroprotective effects of ORZ and micelle-core and chito-micelles on  
252 African Green Monkey Kidney (vero cells), their mitochondrial dehydrogenase activity was  
253 demonstrated using MTT procedure as described elsewhere (Tentor et al., 2017).

### 254 2.14. *In-Vivo* nephroprotection experiment

255 The efficacy of the selected chito-micelles (C-M<sub>3(0.5)</sub>) and the corresponding micelle-core (M<sub>3</sub>)  
256 in preventing nephrotoxicity following their oral delivery was evaluated using Wistar albino rats.  
257 The results were compared to the effect of ORZ suspension (prepared via dispersion of ORZ in  
258 carboxymethyl cellulose solution (0.5%)).

#### 259 2.14.1. Animals

260 Thirty male Wistar albino rats (180-200 g) were used. All rats were supplied with a standard  
261 chow diet and drinking water during the experiment and were caged in open cages at 25 °C with  
262 12 h light and dark cycles at the animal facility of the Faculty of Pharmacy (Ain Shams  
263 University, Egypt). This *in-vivo* study was approved by the Ethics Committee at the Faculty of  
264 Pharmacy, Ain Shams University, Egypt.

#### 265 2.14.2. Experimental design and induction of acute kidney injury (AKI) model

266 All rats were left for one week for acclimatization before starting the experiment. The  
267 experimental model duration was seven days. Rats were divided into five groups (6 rats per  
268 group) as follows:

269 Group I received normal saline orally (normal control)  
270 Group II received IM glycerol solution (positive control)  
271 Group III received ORZ suspension  
272 Group IV received ORZ micelle-core  
273 Group V received ORZ chito-micelles  
274 AKI was induced based on Adedapo et al., work(Adedapo et al., 2021).  
275 For groups (III-V), 1 mL dose of ORZ preparations (50 mg/kg ORZ) was administered via oral  
276 gavage. At the end of the experimental duration, 24 h after glycerol administration, blood  
277 samples were collected from the retro-orbital plexus. Then, serum was separated by cold  
278 centrifugation of the clotted blood at 4000 rpm for 20 min and then serum was aliquoted and  
279 stored at  $-80^{\circ}\text{C}$  for its subsequent use in biochemical tests. Kidney tissues were dissected and  
280 washed with ice-cold saline and stored at  $-80^{\circ}\text{C}$  for the subsequent molecular analysis or fixed in  
281 10% neutral formalin for histopathological examinations.

282

### 283 **2.14.3. Assessment of nephrotoxicity indices**

284 The kidney function markers; serum concentrations of urea and creatinine were determined  
285 spectrophotometrically using a colorimetric assay by using available commercial kits  
286 (Biodiagnostics, Cairo, Egypt).

287

### 288 **2.15. Histopathological assessment and scoring of treated renal tissues**

289 Kidney tissues were fixed in 10% neutral buffered formalin for 72 h. Then, kidney tissues were  
290 trimmed and added in serial grades of ethanols, cleared in xylene, and embedded into Paraplast  
291 tissue embedding media. Then, blocks were prepared and cut by rotatory microtome into  $4\mu\text{m}$   
292 thick tissue sections. Tissue sections were stained by Hematoxylin and Eosin (H&E) and  
293 examined(Gad et al., 2022; Tiboni et al., 2022).

294 Microscopic scoring was done as previously described blindly by the same pathologist. All light  
295 microscopic examination and scoring data were obtained by using the Leica Application module  
296 for histological analysis attached to Full HD microscopic imaging system (Leica Microsystems  
297 GmbH, Germany).

### 298 **2.16. Sirtuin-1 signaling pathway and associated machineries**

#### 299 **2.16.1. Reverse transcription-quantitative real-time polymerase chain reaction(RT-qPCR)**

300 Extraction of total RNA was done using triazol. One  $\mu\text{g}$  total RNA was reversibly transcribed  
301 into cDNA using high-capacity cDNA Synthesis Kit (Thermo Scientific co., USA). qRT-PCR  
302 was performed using power up SYBR (Applied Biosystems) utilizing an ABI 7500 RT-PCR  
303 System (Applied Biosystems, Foster City, CA, USA). Sequences of PCR primer pairs are shown  
304 in **Table 2**. Fold change for the studied mitochondrial antioxidant genes including manganese  
305 superoxide dismutase (MnSOD), uncoupling protein-2 (UCP2) and peroxisome proliferator-  
306 activated receptor gamma coactivator 1-alpha (PGC-1 $\alpha$ ) genes, Autophagy-related genes (ATG  
307 5, 7 and 12) and unc-51 like autophagy activating kinase 1 (ULK1), apoptotic genes as B-cell  
308 lymphoma 2 (Bcl-2), Bcl-2 Associated X (Bax), p53 and p53 upregulated modulator of apoptosis  
309 (PUMA) genes were determined and normalized to  $\beta$ -actin gene as a reference gene. The relative  
310 quantification was then calculated by the expression  $2^{-\Delta\Delta\text{Ct}}$ .

### 311 **2.16.2. Protein assessment by ELISA**

312 Renal homogenate was washed and homogenized in cold phosphate buffer saline (PBS) buffer  
313 then, centrifuged for 20 min at 4,000 rpm at 4 °C, and supernatant was collected. The total  
314 proteins of the homogenate were quantified using a bicinchoninic acid (BCA) assay kit Sigma-  
315 Aldrich (St Louis, MO, USA). Renal assessment of IL-6, IL-1 $\beta$  and TGF- $\beta$  was conducted in  
316 renal tissue homogenate using ELISA assay kits (Bioassay, Biotech, CO., Ltd Hangzhou,  
317 China), All ELISA procedures were done by Hyprep Automated ELISA system (Hyperion Inc,  
318 Miami, FL) according to the manufacturer's instructions.

319

### 320 **2.17. Statistical analysis**

321 All data were expressed as the mean of 3 replicates  $\pm$  SD. The data obtained were compared  
322 using one-way analysis of variance (ANOVA) and the significance of the difference between  
323 formulations was calculated by Tukey-Kramer multiple comparisons using Graph Pad  
324 Instat<sup>®</sup> software (GraphPad Software, California).

325 In vivo data were expressed by mean  $\pm$  SEM. Statistical significance was estimated by One-way  
326 ANOVA followed by Tukey's Post Test.  $P < 0.05$  was considered to be statistically significant.  
327 The IBM SPSS statistics (V.19.0, IBM Corp., USA, 2010) was used for in vivo data analysis.

### 328 **3. Results and discussion**

329 In this study we synthesized both DB (mPEG-PCL) and TB (PCL-PEG-PCL) copolymers to  
330 prepare self assembling micelles for entrapment of ORZ in a comparative manner. Poor

331 solubility and intestinal absorption of ORZ leads to limited bioavailability. Therefore, this work  
332 investigated different micelles prepared from DB and TB copolymers, in an attempt to increase  
333 ORZ bio distribution and efficacy. Refer to literature, particle size and drug release profile of the  
334 prepared micelles were well related to the copolymers attributes like hydrophobicity, molecular  
335 weight ( $M_w$ ), and block arrangement. Along these lines, copolymers structure and crystallinity of  
336 copolymers (hydrophobic/ hydrophilic segments) can be manipulated to form tailored platforms.  
337 mPEG-PCL and PCL-mPEG-PCL PMs bearing the hydrophobic nutraceutical, ORZ, were  
338 formulated, owing to the self-assembling capability of the DB and TB copolymers using thin film  
339 hydration technique, in order to obtain a well determined nanostructure as stated in our previous  
340 works (Elmowafy et al., 2019). Indeed, the inter-attraction between the hydrophilic PEG segment  
341 and water could be at the base of good dissolution and dispersability of hydrophobic drugs like  
342 ORZ in water (Hu et al., 2003). The DB and TB copolymers used in the preparation of ORZ  
343 micelle-core offer different molecular weights of 4 and 5 kDa respectively. The impact of polymer  
344 structure (number of blocks of PEGylated PCL) and polymer to drug ratio on physicochemical  
345 features of micelles was investigated.

346 The composition and physical parameters of the prepared micelle-core are depicted in Table  
347 1. The selected anionic micelles were coated with positively charged CS by electrostatic  
348 interactions and the effect of CS coating was investigated as well. Inclusion of positive charge  
349 has been generally considered beneficial in improving oral absorption (Daeihamed et al., 2017).  
350 The composition and the characteristic physical properties of chito-micelles are outlined in Table  
351 3.

### 352 **3.1. Colloidal parameters of the Micelle-core formulations**

353 The impact of nanosized particles on oral transmucosal permeation and absorption has been well  
354 documented (Daeihamed et al., 2017). Dynamic light scattering revealed that the average diameter  
355 of the micelle-core was maintained below 200 nm, ranging from 97.9 to 117.8 nm. Obviously, the  
356 maximum value of PS was obtained upon using TB copolymer of  $M_w$  5 kDa and polymer to ORZ  
357 ratio of 5:1 “PS value of M3 = 117.8 nm” (table (1)).

358 The results also exhibited that increasing number of blocks of PEGylated PCL and hence  
359 copolymer molecular weight and length yielded extremely significant increase in micelles size at  
360 5:1 polymer to ORZ ratio only ( $p < 0.0001$ ). As the self-assembly of amphiphilic block  
361 copolymers in aqueous solutions involves mostly hydrophobic interactions (Yan and Xie, 2013),

362 these interaction might be potentiated by increasing the hydrophobicity and hence led to large  
363 micelle size (Alibolandi et al., 2015). Our results are in accordance with previously reported  
364 works. However, at higher polymer to ORZ ratio (10:1), MS differences were not remarkable  
365 exhibiting similar smaller micelle-core sizes for both BD and TD copolymers (98.88 vs. 97.9;  
366 insignificant,  $p=0.8872$ ). This might infer the attainment of the well-knit polymeric micelles  
367 structure at this ratio (10:1). The steric hindrance conferred by increasing the hydrophilic PEG  
368 segment might lead to lower secondary agglomeration of the prepared micelles. This was  
369 consistent with As Aboud et al. who reported that increasing poloxamer F127 concentration was  
370 accompanied by a significant decrease in PS owing to the increase in hydrophilic ethylene oxide  
371 groups and hence steric hindrance preventing aggregate formation (Aboud et al., 2020).

372 The prepared nanovehicles were revealed to be stable with respect to narrow size distribution and  
373 negative surface charge. It can be noted that the PDI values were acceptable (0.219- 0.381)  
374 indicating particles homogeneity and monodispersion. As for surface charge, the micelle-  
375 core possessed negative charge with ZP values fitted between  $-12.6\pm 2.1$  and  $-29.2\pm 2.54$  mV. This  
376 could be attributed to the ionized carboxyl groups of PCL hydrophobic segment. Compared with  
377 TB based micelle-core, lower ZP values were obtained for DB based micelle-core that could be  
378 assigned to the shielding effect of the neutral PEG shell. Previous studies revealed that  
379 increasing the polymer molecular weight was associated with increasing the negativity of ZP  
380 values, which may be attributed to the increase of hydrophobicity of the polymer as a function of  
381 the molecular weight. Unlike its impact on PS, shifting from 5:1 to 10:1 polymer to ORZ ratio  
382 displayed statistically invariant surface charge ( $p > 0.05$ ).

### 383 **3.2. ORZ entrapment efficiency and loading in the Micelle-core formulation**

384 The percent of ORZ entrapped within micelle-core was found to be in the range of 67.28 to  
385 93.87% while the DL% ranged between 7.93 and 17%. Higher values of EE% and DL% were  
386 observed in TB micelle-core rather than DB ones. Both EE% and DL% seemed to be strongly  
387 correlated with the number of blocks and polymer to ORZ ratio ( $p < 0.05$ ).

388 Concerning EE%, the feed ratio of the polymer to drug altered the amount of entrapped drug  
389 in micellar system as the EE% of micelle-core was increased by 9-12% along with the increase in  
390 the polymer to ORZ ratio from 5:1 to 10:1. Higher impact on EE% was noticed for copolymer  
391 type, exhibiting 15-18% increase in EE% when shifting for DB copolymer to TB counterpart.

392 The highest EE% value was obtained in M4 prepared using TB copolymer at 10:1 polymer to  
393 ORZ ratio. This could be attributed to the greater amount of copolymer available to  
394 accommodate drug during micelles' formation. Additionally, the higher hydrophobicity of TB  
395 copolymer could intensify the hydrophobic interactions between ORZ and hydrophobic chains of  
396 the copolymer resulting in reduced drug distribution to the aqueous phase (Feng et al., 2012).  
397 These findings could reflect the competence of TB copolymer based micelle-core to retain shell  
398 integrity affecting ORZ entrapment.

399 As for the DL% , its trend was noticeably different from that of EE%. Likewise its impact on  
400 EE%, utilizing TB copolymer was demonstrated to favor significantly DL% optimization relative  
401 to BD copolymer. Most notably, varying D/P ratio exhibited a significant antagonistic effect on  
402 DL% ( $p < 0.05$ ). As depicted, increasing polymer molecular weight resulted in a significant  
403 reduction in %EE. Increasing the polymer amount led to a concomitant increase in the total mass  
404 of micelle-core. As a result, the DL% values significantly decreased when shifting from 5:1 to  
405 10:1 polymer to ORZ ratio ( $p < 0.05$ ). Maximum DL% was achieved when TB copolymer was  
406 used at 5:1 polymer to ORZ ratio (DL% value = 17.00%).

407 It is worth mentioning that there was a positive correlation between PS and DL% as when the  
408 drug incorporated inside the micelle-core, its volume increased accordingly (Feng et al., 2012).  
409 Similar findings were observed when using **triblock (PCL-PEG-PCL) and pentablock (PLA-**  
410 **PCL-PEG-PCL-PLA)** in loading auraptene (Jalilzadeh et al., 2020).

411 Based on the previous findings, M1 and M3 formulae prepared using 5:1 polymer to ORZ ratio  
412 and exhibited the highest DL% values (13.45 % and 17% respectively) were selected for CS  
413 coating and further investigations.

### 414 **3.3. Impact of chitosan coating on colloidal parameters of the micelle-core**

415 The formed coating layer on the micelle-core surface was found to impact the colloidal  
416 parameters of the micelle-core. Compared to the original micelle-core size, whatever the  
417 copolymer structure, the selected CS coated micelle-core (chito-micelles) exhibited significantly  
418 large diameters ( $p < 0.05$ ). For both DB and TB copolymers, when the CS concentration  
419 increased from 0.25 to 0.5%, the MS increased accordingly ( $p < 0.05$ ). Besides, the chito-micelles  
420 size increased significantly upon further increase in CS concentration from 0.5 to 1%, yet,  
421 yielding PS > 200 nm. The highest CS concentration used (1%) was accompanied with a

422 significant increase in chito-micelles size (respective values for DB and TB chito-micelles were  
423  $411 \pm 12.75$  and  $480 \pm 10.68$ ;  $p < 0.05$ ) as profiled in Table 3. The increased thickness  
424 accompanied with increasing CS concentration led to particles sizes enlargement.

425 Similarly, PDI showed strong dependence on CS coating referring to heterodisperse colloidal  
426 systems. For example, upon using the highest CS concentration (1%) in both DB and TB  
427 copolymers, the resultant formulations were found to be more polydisperse (respective values of  
428 0.61 and 0.927). The concomitant increase in PS and PDI with the increase in CS concentration  
429 was noted in previous investigations (Pandit et al., 2017).

430 Meanwhile, the total nanoparticle charge reversed from negative charge (for micelle-core) to  
431 positive charge (for micelle-core/CS shell nanoparticle), pinpointing the deposition of CS layer  
432 on the surface of micelle-core and hence the infallible coating. This came in line with previous  
433 literature for CS coated solid lipid nanoparticles (Kamel et al., 2017) and CS coated nano-  
434 liposomes (Nguyen et al., 2014). The magnitude of the zeta potential values was noticeably  
435 increased with the increment in CS concentration. Importantly, the high values of absolute zeta  
436 potential indicated high *in vitro* stability.

437 It is worth mentioning that using CS concentrations up to 0.5% yielded coated nanoparticle  
438 with size less than 200 nm that are optimal for the felicitous diffusion of nanoparticles through  
439 intestinal mucus layer (Yun et al., 2013).

440

#### 441 **3.4. Morphological examination**

442 Fig.1 shows a representative TEM image of the selected micelle-core (M3) and the  
443 corresponding chito-micelles (C-M3<sub>(0.5)</sub>). As revealed, the prepared nanovehicles were nearly  
444 spherical with a size similar to particle size measurement using the dynamic light scattering  
445 technique. The particle surface was very smooth and no drug crystal was visible. CS coating was  
446 confirmed in the chito-micelles. Sizes are in agreement with the DLS analysis.

#### 447 **3.5. *In-vitro* release study and release kinetics**

448 In order to investigate the effect of number of PCL copolymer blocks on one side and CS coating  
449 on the other side on ORZ release behavior from the prepared nanoparticle, the *in-vitro* release  
450 study of ORZ from selected micelle-core formulae (M1 and M3) and the corresponding chito-  
451 micelles (C-M1<sub>(0.5)</sub> and C-M13<sub>(0.5)</sub>) was performed using ORZ ethanolic solution as a control, as

452 shown in Fig. 2. ORZ solution was completely released within 8 h (data not shown) while all  
453 selected formulae exhibited sustained release properties that seemed to be well-linked to the  
454 molecular structural features of micelles and their further coating step.

455 For all the tested micelle-core formulae and chito-micelles, the accumulated release at 24 h  
456 exhibited two-stage release profile with an initial burst discharge in the first 2 h followed by a  
457 slower drug release for 24 h. The initial burst effect is correlated with the easily desorbed  
458 corona-entrapped drug while the slower drug release was attributed to the entrapped drug  
459 diffusion from the micelle-core. The initial burst release of ORZ in TB co-polymer based  
460 micelle-core (M3) was significantly lower than that in BD based one (M1). This two-phase  
461 release profile of the polymeric micelles came in line with previous literature (Feng et al., 2012;  
462 Gong et al., 2010).

463 As a consequence of CS coating, a significantly lower burst release was detected for Chito-  
464 micelles than that of the corresponding micelle-cores. The reduced burst discharge of the CS  
465 coated nanocarriers was demonstrated previously (Dasineh et al., 2021; Lu et al., 2019). Besides,  
466 after the initial rapid release, chito-micelles resulted in more sustained release. The cumulative  
467 release of ORZ from C-M1<sub>(0.5)</sub> and C-M13<sub>(0.5)</sub> was 53.9%, and 46.86%, after 24 h, respectively.  
468 The slow diffusion of ORZ from the prepared nanosystems ensured the maintenance of constant  
469 ORZ concentration for a relatively long period of time. These findings were in agreement with  
470 Nguyen et al. who reported the concentration-dependent retarding impact of CS coating on the  
471 Berberine hydrochloride release from CS coated nano-liposomes (Nguyen et al., 2014).

472 ORZ release from selected uncoated and coated micelles showed a good fit to the Higuchi model  
473 with the highest linearity ( $r^2 = 0.923-0.947$ ). Similarly, fitting to Peppas model exhibited  
474 acceptable linearity ( $r^2 = 0.90-0.961$ ) with values of around 0.20 (Fickian), indicating diffusion  
475 mediated drug release.

### 476 3.6. DSC

477 DSC study was performed to assess the physical stability of the nanoplateforms and encapsulation  
478 of ORZ inside them. The DSC curves obtained are shown in Fig. 3. ORZ thermogram displayed  
479 endothermic melting peaks at 60 °C, 99 °C & 160 °C followed by exothermic peak at 175 °C  
480 indicating drug decomposition at higher temperature. This thermal behavior proved the  
481 crystalline nature of the drug. As for thermograms of DB & TB copolymers, their DSC  
482 thermograms showed endothermic melting peaks at 60 & 140 °C for DB & 60 & 100 °C for TB



483 as shown in Fig.3 . Upon investigating the thermograms of uncoated and CS coated DB and TB  
484 micelles, it was obvious that ORZ melting peaks disappeared upon encapsulation inside both CS  
485 coated and uncoated micelles indicating that ORZ was present within the micelles in an  
486 amorphous state proving its dissolution inside the matrix(Ruktanonchai et al., 2009).

487

### 488 3.7. FT-IR

489 FTIR was employed to disclose the possible interaction between ORZ and the polymeric  
490 micelles and prove the coating of the micelles with CS as shown in Fig.4. In generated spectrum  
491 for ORZ, the different groups were represented by the following peaks: C-H stretching of alkanes  
492 at  $2954\text{ cm}^{-1}$  of alkanes, C=C stretching of aromatic hydrocarbons at  $1602/\text{cm}$ , intermolecular H  
493 bonded OH stretching of alcohol at  $3298.68/\text{cm}$  and C=O stretching enolic groups of ester at  
494  $1689.34/\text{cm}$  of ester(Rawal et al., 2018). The DB copolymer showed characteristic high-intensity  
495 signals at  $1726.64\text{ cm}^{-1}$  for C=O vibrations, indicating the crystalline nature of the micelle  
496 core(Elmowafy et al., 2019), and weak bands at  $3448.17\text{ cm}^{-1}$  for OH stretching  
497 vibrations. Higher intensity signals were more evident at  $1726.64$  in case of TB copolymer  
498 indicating higher crystallinity arising from the 2<sup>nd</sup> PCL moiety.

499 In the spectrum of CS coated DB & TB micelles, the characteristic peak located at  $3447\text{ cm}^{-1}$   
500 represented intermolecular hydrogen bonding and stretching vibration of  $-\text{NH}_2$  as well as  $-\text{OH}$   
501 groups of CS. Another typical peak for CS, is the peak at  $2900\text{ cm}^{-1}$  which  
502 represented the stretching vibration of C-H from alkyl groups, whereas peaks at around  $1657$   
503  $\text{cm}^{-1}$  (C=O stretching of amide I) and  $1320\text{ cm}^{-1}$  (C-N stretching of amide III), respectively  
504 confirmed the presence of residual N-acetyl groups. Moreover, the presence of bands at  $1428$  and  
505  $1360\text{ cm}^{-1}$  proved the CH<sub>2</sub> bending besides  $-\text{CH}_3$  symmetrical deformations  
506 respectively, while that at  $1158\text{ cm}^{-1}$  could be attributed to asymmetric stretching of the C-O-C  
507 bridge. Besides, the bands at  $1066$  and  $1029\text{ cm}^{-1}$  were related to C-O stretching.

508 However, in the spectrum of ORZ-DB copolymer micelles (M2), ORZ-TB copolymer micelles  
509 and CS coated micelles, noticeable weakening of the characteristic peaks of C-O and S-O  
510 stretching of ORZ as well as characteristic peaks of the different copolymers in addition to CS  
511 were observed. Such findings indicated the incorporation and amorphization of ORZ inside the  
512 different micelles.

513

### 514 **3.8. Stability studies**

515 Colloidal stability is a major concern with clinical oral administration of nanovehicles. In this  
516 regard, the effect of short term storage on the selected chitomicelles was monitored for four  
517 weeks at 4°C. As observed in Table 4, negligible variations in PS were recognized over four  
518 weeks compared to the initial results (0 day) ( $p>0.05$ ). However, a slight increase in PS, yet non-  
519 significant, was revealed at the end of storage period “28 days” ( $p>0.05$ ).

520 It is worthy to note that values of PDI (0.424-0.485) and ZP (33.2- 37.8) exhibited no significant  
521 changes over four weeks ( $p>0.05$ ). Referring to literature, CS coated nanoplatfroms exhibited  
522 excellent stability(Quagliariello et al., 2018).

523 Furthermore, to mimic their *in vivo* physiological intestinal conditions, *in vitro* stability study of  
524 the selected micelles in SIF was conducted at 37°C. The PS and PDI of micellar dispersions  
525 remained nearly unchanged after 6 h incubation ( $p>0.05$ ). These results confirmed the stability of  
526 the micelles in the intestinal environment. This was consistent with previous findings(Ji et al.,  
527 2018).

528 Considering the above mentioned findings, TB based nanoplatfrom (C-M3<sub>(0.5)</sub>) was a promising  
529 nanoplatfrom for ORZ with respect with high drug loading and prolonged release and were  
530 subjected to subsequent *in vitro* and *in vivo* investigations. For comparative purposes, to  
531 elucidate the influence of CS coating, the uncoated micelles-core (M3) were also examined.

### 532 **3.9. Mucoadhesion**

533 The *in vitro* mucoadhesiveness of the selected chito-micelles were demonstrated via the  
534 measurement of their  $\zeta$ -potential values. Following the incubation of chito-micelles with mucin,  
535 a remarkable 3.72 fold reduction in the magnitude of the zeta potential value was attained  
536 ( $37.4\pm 0.781$  versus  $10.03\pm 0.36$ ). This behavior indicated the paramount ionic interaction  
537 between the positive charge of CS coated micelles by negatively charged mucin  
538 groups(Elmowafy and Soliman, 2019) and hence considerable mucoadhesivity. This was  
539 consistent with previously published reports(Hejjaji et al., 2018; Silva et al., 2017). This was not  
540 the case in the micelle-core-mucin mixture that exhibited negative zeta potential value of -  
541  $10.5\pm 5.23$ . Similarly, the PS of chito-micelles was significantly increased in the presence of  
542 mucin ( $318.9\pm 2.43$  nm) ( $p < 0.05$ ).

### 543 **3.10. *In vitro* anti-oxidant potential**

544 ORZ has been documented to possess antioxidant activity. The results of DPPH assay depicted  
545 that the formulation process of micelle-core and chito-micelles did not interfere with ORZ  
546 antioxidant capacity in vitro. While both micelle-core and chito-micelles exhibited free radical  
547 scavenging ability, the chito-micelles possessed greater antioxidant activity ( $92.63 \pm 1.59\%$ ) as  
548 compared to micelle-core ( $78.56 \pm 2.62\%$ ). Interestingly, chito-micelles showed similar DPPH  
549 scavenging to the standard antioxidant; ascorbic acid ( $98.76 \pm 0.62\%$ ). Greater antioxidant  
550 activity of CS coated nanosystems as compared to its uncoated ones was demonstrated  
551 earlier (Quagliariello et al., 2018).

### 552 **3.11. *In vitro* cytocompatibility**

553 The available literature data point to the biocompatibility of PCL copolymers on different cell  
554 lines (Gong et al., 2013; Łukasiewicz et al., 2021). Safe effect on cell lines was reported for  
555 pegylated nanoparticles as well as CS based nanoparticles. Specifically, no cytotoxicity on caco-2  
556 cells (model of intestinal epithelium) have been revealed for CS nanoparticles (Liu et al.,  
557 2013). This was stemmed from the fact that they were formed bio-acceptable components.

558 MTT assay was employed to investigate the proliferation of VERO cells after 24  
559 h incubation of different concentrations of unformulated ORZ, ORZ micelle-core and the  
560 corresponding chito-micelles. The highest cytocompatible effects were observed in chito-  
561 micelles compared to micelle-core and free ORZ obtained by MTT assay. As evident in  
562 Fig. 5, unformulated ORZ treatment for 24 h dramatically decreased vero cells viability in a  
563 concentration dependent manner reaching only 19.45% cell viability at 250  $\mu\text{g/mL}$ . On the other  
564 hand, the viability of vero cells treated with micelle-core and chito-micelles at the highest  
565 concentration (250  $\mu\text{g/mL}$ ) was about 45% and 50% higher, respectively versus ORZ-treated  
566 cells. Furthermore, statistical difference in cell viability was noticed between formulated ORZ  
567 and unformulated ORZ at all the tested concentrations ( $p < 0.05$ ). More importantly, chito-  
568 micelles were revealed to have better cytocompatibility properties than did micelle-core. Worthy  
569 to note that chito-micelles showed slightly 70.82% cell viability at the highest concentration (250  
570  $\mu\text{g/mL}$ ), the minimum threshold for cytotoxicity.  $\text{IC}_{50\%}$  of the micelle-core and its  
571 corresponding chito-micelles was found to be 383.1 and 415.8  $\mu\text{g/mL}$  respectively, being 4.41  
572 fold and 4.79 fold increase in cell viability when compared to free ORZ which showed moderate  
573 cytotoxicity ( $\text{IC}_{50} = 86.7 \mu\text{g/mL}$ ). This indicates the positive effect of CS on improving the safety

574 of chito-micelles. Thus, theselected formulawas tolerable and would not cause renal cytotoxicity  
575 (IC50>

### 576 **3.12. *In vivo* pharmacodynamic study**

577 Indeed, the bioavailability of a drug after administration and its pharmacodynamics are strongly  
578 correlated. Substantial drug bioavailability could be reflected by its intensified pharmacological  
579 effect. In line, the nephroprotective effect of ORZ and its uncoated and coated micelles were  
580 investigated in glycerol-induced AKI model, strongly reflectingrhabdomyolysis(Adedapo et al.,  
581 2021).IM injection of hypertonic concentration of glycerol was reported to bring about myolysis,  
582 hemolysis and tubular nephrotoxic effects induced by renal exposurotoheme proteins and their  
583 degradation products(BALIGA et al., 1999; de Jesus Soares et al., 2007).Additionally, glycerol-  
584 induced AKI was accompanied by myoglobin toxicity, oxidative damage, inflammation  
585 andapoptois(Adedapo et al., 2021; Wu et al., 2017). The protective effect of ORZon cardio-renal  
586 syndrome, induced by administration of high-fat-sucrose diet and cisplatin injection, has  
587 beenconfirmed with respect to improvement of kidney function parametersand glomerular  
588 filteration rate(Al-Okbi et al., 2019).

589 A significant boost in serum urea and creatinine levels of the toxicant AKI group was revealed,  
590 an attestation to the occurrence of glycerol-induced renal damage, **Fig.6**

591 . This came in line with previous literature (Hashish et al., 2020). The disrupted serum urea and  
592 creatinine levels in AKI group were significantly ameliorated by the pretreatment of rats  
593 withORZ either suspension, micelle-core or chito-micelles ( $p < 0.05$ ).ORZ suspension and  
594 micelle-core descended the kidney function parameters by approximately 1.35 -1.65 folds for  
595 urea and 1.36-2 folds for creatinine respectively relative to AKI group ( $p < 0.05$ ).Yet, the greatest  
596 impact was noticed with chito-micelles. Chito-micelles showed nearly two- and four-fold decline  
597 in serum urea and creatinine levels respectively compared to AKI group ( $p < 0.05$ ), approaching  
598 that of the normal control group ( $p > 0.05$ ).

599 The superior biological performance of chito-micelles can be credited to several factors. First,  
600 the mucoadhesive nature and paracellular permeability enhancing effect of the outer CS layer  
601 helps increasing intestinal absorption of ORZ(Liu et al., 2013). Second, CS itself has renal  
602 protection and targeting properties as a result of its increased renal concentration due to its  
603 preferential distribution to the kidney(Chou et al., 2015). In a previous study conducted by Liu et  
604 al. that CS nanoparticles(mean diameter of 215.34 nm, zeta potential of 19.26 mV)distributed

605 mainly in liver, kidney and heart and this was attributed to its infiltration into the mucus layer  
606 and long residence in blood circulation(Liu et al., 2013). Third, the nano size and  
607 sustained release properties of the formed chito-micelles. The beneficial effects of ORZ in  
608 reversing renal dysfunction could be related to its anti-inflammatory, cytoprotective, and  
609 antioxidant actions in the kidney. To elucidate these benefits, the renal morphological alterations  
610 and underlying molecular mechanism were thoroughly investigated.

611

### 612 **3.13. Chitosan coated and uncoated ORZ attenuated histopathological alteration of glycerol** 613 **induced acute kidney injury**

614 Histological examination of H&E stained kidney sections (**Fig. 7**) showed no  
615 histopathological changes in the control group. However, glycerol induced acute kidney  
616 injury showing abundant necrotic and hyperesophilic tubular segments areas losing its  
617 luminal border integrity as well as cystic dilatation of some tubules and higher records of  
618 intraluminal desquamated epithelial cells and casts. Moreover, congested interstitial blood  
619 vessels were also shown. Treatment with free ORZ showed diffuse moderate tubular  
620 degenerative changes with many figures of vacuolar degeneration of various tubular segments  
621 associated with necrotic cells, mild focal records of intraluminal cellular casts and mild  
622 congested interstitial blood vessels. On the other hand, uncoated micelle group showed  
623 protective effects with moderate records of tubular vacuolar degenerative changes associated  
624 with few focal records of tubular necrosis. Chitosan coated ORZ group demonstrated superior  
625 protective effects through mild focal records of tubular degenerative changes and nuclear  
626 pyknosis. Besides, abundant records of intact nephronal segments were shown with intact  
627 vasculatures of the renal corpuscles (**Fig. 7**). Scoring of the kidney tissues showed marked  
628 congestion in the blood vessels, associated with severe tubular necrosis and abundance of  
629 luminal casts with moderate cystic dilatation in glycerol induced acute kidney injury as  
630 compared to the control group. In alignment, treatment with free ORZ didn't show significant  
631 improvement in renal damage scoring. However, moderate improvement was observed in  
632 uncoated micelle group, while, significant protection was detected in Chitosan coated  $\gamma$  ORZ  
633 group showing mild tubular necrosis and mild luminal casts (**Fig. 7**).

634

635 **3.14. Sirtuin-1 signaling pathway and associated machineries**

636 **3.14.1. Chitosan coated and uncoated ORZ increased sirtuin-1 levels in glycerol induced**  
637 **acute kidney injury**

638 A significant decrease was found in Sirtuin-1 levels in AKI as compared to the control group.  
639 Otherwise, treating with ORZ uncoated or CS coated micelles significantly increased sirtuin-1  
640 levels by 16.9% and 11.2% as compared to AKI group (**Fig. 8**).

641 **3.14.2. Chitosan coated and uncoated ORZ increased the antioxidant states in glycerol**  
642 **induced acute kidney injury**

643 Antioxidant state was significantly suppressed in acute kidney injury evidenced by significant  
644 decrease in MnSOD, UCP2 and PGC-1 $\alpha$  by 51.2%, 76.2% and 67% respectively. However, all  
645 free ORZ and ORZ incorporated in uncoated and coated micelles significantly stimulated the  
646 antioxidant state as shown in **Fig. 9**.

647 **3.14.3. Chitosan coated and uncoated ORZ activated autophagy in glycerol induced acute**  
648 **kidney injury**

649 Autophagy was significantly abrogated in AKI group as shown in **Fig. 10** with remarkable  
650 decrease in expression of ATG 5,7, 12 and in ULK-1. On the other side, ORZ uncoated and CS  
651 coated micelles significantly increased the expression of autophagy regulated genes.

652 **3.14.4. Chitosan coated and uncoated ORZ abrogated inflammation in glycerol induced**  
653 **AKI**

654 Acute kidney injury is associated with increased inflammation which was clearly shown in our  
655 results with significant increase in IL-6 by 96.7% and in IL-1 $\beta$  by 115.5% and in TGF- $\beta$  by  
656 56.9% as compared to the control group. Reversibly, Chitosan coated and uncoated ORZ  
657 micelles significantly resolved this inflammatory changes as shown in **Fig. 11**.

658 **3.14.5. Chitosan coated and uncoated ORZ diminished apoptotic changes in glycerol**  
659 **induced acute kidney injury**

660 The expression of apoptotic genes p53, PUMA and Bax/Bcl2 ratio were significantly induced in  
661 AKI as shown in **fig. 12**. Nevertheless, Chitosan coated and uncoated ORZ micelles significantly  
662 diminished this apoptotic state.

663 To sum up, free ORZ failed to protect against glycerol induced AKI with moderate necrotic and  
664 degenerative changes. However, Chitosan coated and uncoated ORZ micelles significantly  
665 restored renal antioxidant states through the upregulation of MnSOD, UCP2 and PCG-1 $\alpha$  genes.  
666 This was associated with autophagy activation via increasing the expression of ATG 5, ATG 7,  
667 ATG 12 and ULK-1. Furthermore, this was accompanied by inhibiting inflammation through  
668 decreasing renal levels of IL-6, IL-1 $\beta$  and TGF- $\beta$  which leads to diminishing apoptosis through  
669 decreased renal expression of p53, PUMA and BAX/Bcl2 ratio. All these effects are reported to  
670 be through increasing renal sirtuin-1 levels.

671

#### 672 **4. Conclusion**

673 Chitosan (CS) coated and uncoated copolymer micelles of the phytochemical drug, ORZ were  
674 successfully prepared. The prepared micelles showed favorable nanosize, zeta potential and PDI.  
675 Additionally, the prepared micelles exhibited high DL% & EE% for ORZ in addition to  
676 sustained drug release pattern. Both micelles showed cytocompatibility on Vero® cells of the  
677 kidney with the chito-micelles showing higher safety than uncoated. The modification and  
678 coating of micellar surface with chitosan was proved by the size increase and charge reversal  
679 upon coating with chitosan, in addition to the DSC and FTIR studies. The nephroprotective  
680 effect of the prepared micelles against glycerol induced acute renal impairment in rats was  
681 proved through measurement of nephrotoxic indices, serum urea & creatinine levels in rats serum,  
682 histopathological examination, biochemical measurement of sirtulin-1 levels, antioxidant,  
683 autophagy and apoptotic genes in different experimental groups. Both chitosan coated and  
684 uncoated micelles exhibited better nephroprotective potential compared to free ORZ suspension.  
685 Additionally, CS coated micelles were more effective on restoring normal kidney parameters to  
686 than uncoated ones. Hence, these newly developed nanoformulations of the phytochemical drug  
687 ORZ are considered promising platforms for protection against acute kidney impairment.

688

#### 689 **References**

690 Aboud, H.M., Mahmoud, M.O., Abdeltawab Mohammed, M., Shafiq Awad, M., Sabry, D.,  
691 2020. Preparation and appraisal of self-assembled valsartan-loaded amalgamated Pluronic  
692 F127/Tween 80 polymeric micelles: boosted cardioprotection via regulation of Mhrt/Nrf2 and  
693 Trx1 pathways in cisplatin-induced cardiotoxicity. *Journal of drug targeting* 28, 282-299.

694 Adedapo, A.A., Osaretin, E.R., Falayi, O.O., Oyagbemi, A.A., Ogunpolu, B.S., Omobowale,  
695 T.O., Oguntibeju, O.O., Yakubu, M.A., 2021. Ramipril blunts glycerol-induced acute renal  
696 failure in rats through its antiapoptosis, anti-inflammatory, antioxidant, and renin-inhibiting  
697 properties. *Journal of Basic and Clinical Physiology and Pharmacology* 32, 225-235.

698 Ahmad, Z., Shah, A., Siddiq, M., Kraatz, H.-B., 2014. Polymeric micelles as drug delivery  
699 vehicles. *Rsc Advances* 4, 17028-17038.

700 Al-Okbi, S.Y., Mohamed, D.A., Hamed, T.E., Al-Siedy, E.S., 2019. Rice bran as source of  
701 nutraceuticals for management of cardiovascular diseases, cardio-renal syndrome and hepatic  
702 cancer. *Journal of Herbmec Pharmacology* 9, 68-74.

703 Aldalaen, S., Nasr, M., El-Gogary, R.I., 2020. Angiogenesis and collagen promoting  
704 nutraceutical-loaded nanovesicles for wound healing. *Journal of Drug Delivery Science and*  
705 *Technology* 56, 101548.

706 Alibolandi, M., Ramezani, M., Abnous, K., Sadeghi, F., Hadizadeh, F., 2015. Comparative  
707 evaluation of polymersome versus micelle structures as vehicles for the controlled release of  
708 drugs. *Journal of Nanoparticle Research* 17, 1-16.

709 Aslam, S., Jahan, N., Rehman, K.-u., Asi, M.R., 2020. Development of sodium lauryl sulphate  
710 stabilized nanosuspension of *Coriandrum sativum* to enhance its oral bioavailability. *Journal of*  
711 *Drug Delivery Science and Technology* 60, 101957.

712 Azab, A.E., Albasha, M.O., Elsayed, A.S.I., 2017. Prevention of nephropathy by some natural  
713 sources of antioxidants. *Yangtze Medicine* 1, 235.

714 BALIGA, R., UEDA, N., WALKER, P.D., SHAH, S.V., 1999. Oxidant mechanisms in toxic  
715 acute renal failure. *Drug metabolism reviews* 31, 971-997.

716 Cheng, W., Zeng, X., Chen, H., Li, Z., Zeng, W., Mei, L., Zhao, Y., 2019. Versatile  
717 polydopamine platforms: synthesis and promising applications for surface modification and  
718 advanced nanomedicine. *Acs Nano* 13, 8537-8565.

719 Chou, C.-K., Li, Y.-C., Chen, S.-M., Shih, Y.-M., Lee, J.-A., 2015. Chitosan prevents  
720 gentamicin-induced nephrotoxicity via a carbonyl stress-dependent pathway. *BioMed research*  
721 *international* 2015.

722 Daeihamed, M., Haeri, A., Ostad, S.N., Akhlaghi, M.F., Dadashzadeh, S., 2017. Doxorubicin-  
723 loaded liposomes: enhancing the oral bioavailability by modulation of physicochemical  
724 characteristics. *Nanomedicine* 12, 1187-1202.



725 Dasineh, S., Akbarian, M., Ebrahimi, H.A., Behbudi, G., 2021. Tacrolimus-loaded chitosan-  
726 coated nanostructured lipid carriers: preparation, optimization and physicochemical  
727 characterization. *Applied Nanoscience* 11, 1169-1181.

728 de C Coelho Junior, É., Maciel, P.P., de AF Muniz, I., Silva, H.Y., de Sousa, S.A., Valença,  
729 A.M., Dias, R.T., Batista, A.U., Figueiredo, L.R., de Medeiros, E.S., 2021. Poloxamer  
730 407/chitosan micelles can improve  $\alpha$ -Tocopherol effect on oral keratinocytes proliferation.  
731 *Journal of Materials Research* 36, 1447-1455.

732 de Jesus Soares, T., Volpini, R.A., Francescato, H.D., Costa, R.S., da Silva, C.G., Coimbra,  
733 T.M., 2007. Effects of resveratrol on glycerol-induced renal injury. *Life sciences* 81, 647-656.

734 El-Gogary, R.I., Nasr, M., Rahsed, L.A., Hamzawy, M.A., 2022. Ferulic acid nanocapsules as a  
735 promising treatment modality for colorectal cancer: Preparation and in vitro/in vivo appraisal.  
736 *Life Sciences* 298, 120500.

737 Elmowafy, E., El-Derany, M.O., Biondo, F., Tiboni, M., Casettari, L., Soliman, M.E., 2020.  
738 Quercetin loaded monolaurate sugar esters-based niosomes: Sustained release and mutual  
739 antioxidant—hepatoprotective interplay. *Pharmaceutics* 12, 143.

740 Elmowafy, E., Gad, H., Biondo, F., Casettari, L., Soliman, M.E., 2019. Exploring optimized  
741 methoxy poly (ethylene glycol)-block-poly ( $\epsilon$ -caprolactone) crystalline cored micelles in anti-  
742 glaucoma pharmacotherapy. *International journal of pharmaceutics* 566, 573-584.

743 Elmowafy, E., Soliman, M.E., 2019. Losartan-chitosan/dextran sulfate microplex as a carrier to  
744 lung therapeutics: dry powder inhalation, aerodynamic profile and pulmonary tolerability.  
745 *International journal of biological macromolecules* 136, 220-229.

746 Feng, R., Song, Z., Zhai, G., 2012. Preparation and in vivo pharmacokinetics of curcumin-loaded  
747 PCL-PEG-PCL triblock copolymeric nanoparticles. *International journal of nanomedicine* 7,  
748 4089.

749 Gad, H.A., Mansour, M., Abbas, H., Malatani, R.T., Khattab, M.A., Elmowafy, E., 2022. “Plurol  
750 will not miss the boat”: A new manifesto of galantamine conveyance. *Journal of Drug Delivery*  
751 *Science and Technology*, 103516.

752 Ghaderi, S., Ghanbarzadeh, S., Mohammadhassani, Z., Hamishehkar, H., 2014. Formulation of  
753 gammaoryzanol-loaded nanoparticles for potential application in fortifying food products.  
754 *Advanced pharmaceutical bulletin* 4, 549.

755 Gong, C., Deng, S., Wu, Q., Xiang, M., Wei, X., Li, L., Gao, X., Wang, B., Sun, L., Chen, Y.,  
756 2013. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable  
757 polymeric micelles. *Biomaterials* 34, 1413-1432.

758 Gong, C., Wei, X., Wang, X., Wang, Y., Guo, G., Mao, Y., Luo, F., Qian, Z., 2010.  
759 Biodegradable self-assembled PEG–PCL–PEG micelles for hydrophobic honokiol delivery: I.  
760 Preparation and characterization. *Nanotechnology* 21, 215103.

761 Hashish, E., Elgaml, S., El-Fattah, A., Shalaby, S., Abdelaziz, S., 2020.  $\beta$ -Amyrin  
762 supplementation ameliorates the toxic effect of glycerol in the kidney of rat model. *Human &*  
763 *experimental toxicology* 39, 930-937.

764 Hejjaji, E.M., Smith, A.M., Morris, G.A., 2018. Evaluation of the mucoadhesive properties of  
765 chitosan nanoparticles prepared using different chitosan to tripolyphosphate (CS: TPP) ratios.  
766 *International journal of biological macromolecules* 120, 1610-1617.

767 Hou, Y., Wang, H., Zhang, F., Sun, F., Xin, M., Li, M., Li, J., Wu, X., 2019. Novel self-  
768 nanomicellizing solid dispersion based on rebaudioside A: a potential nanoplatform for oral  
769 delivery of curcumin. *International journal of nanomedicine* 14, 557.

770 Hu, Y., Jiang, X., Ding, Y., Zhang, L., Yang, C., Zhang, J., Chen, J., Yang, Y., 2003. Preparation  
771 and drug release behaviors of nimodipine-loaded poly (caprolactone)–poly (ethylene oxide)–  
772 polylactide amphiphilic copolymer nanoparticles. *Biomaterials* 24, 2395-2404.

773 Jalilzadeh, N., Samadi, N., Salehi, R., Dehghan, G., Iranshahi, M., Dadpour, M.R., Hamishehkar,  
774 H., 2020. Novel nano-vehicle for delivery and efficiency of anticancer auraptene against colon  
775 cancer cells. *Scientific reports* 10, 1-19.

776 Ji, S., Lin, X., Yu, E., Dian, C., Yan, X., Li, L., Zhang, M., Zhao, W., Dian, L., 2018. Curcumin-  
777 loaded mixed micelles: Preparation, characterization, and in vitro antitumor activity. *Journal of*  
778 *Nanotechnology* 2018.

779 Kamel, K.M., Khalil, I.A., Rateb, M.E., Elgendy, H., Elhawary, S., 2017. Chitosan-coated  
780 cinnamon/oregano-loaded solid lipid nanoparticles to augment 5-fluorouracil cytotoxicity for  
781 colorectal cancer: extract standardization, nanoparticle optimization, and cytotoxicity evaluation.  
782 *Journal of agricultural and food chemistry* 65, 7966-7981.

783 Kengkittipat, W., Kaewmalun, S., Khongkow, M., Iempridee, T., Jantimaporn, A.,  
784 Bunwatharaphansakun, P., Yostawonkul, J., Yata, T., Phoolcharoen, W., Namdee, K., 2021.

785 Improvement of the multi-performance biocharacteristics of cordycepin using BiloNiosome-  
786 core/chitosan-shell hybrid nanocarriers. *Colloids and Surfaces B: Biointerfaces* 197, 111369.

787 Kumar, R., Sirvi, A., Kaur, S., Samal, S.K., Roy, S., Sangamwar, A.T., 2020. Polymeric micelles  
788 based on amphiphilic oleic acid modified carboxymethyl chitosan for oral drug delivery of bcs  
789 class iv compound: Intestinal permeability and pharmacokinetic evaluation. *European Journal of*  
790 *Pharmaceutical Sciences* 153, 105466.

791 Lamie, C., Elmowafy, E., Attia, D.A., Elmazar, M.M., Mortada, N.D., 2022. Diversifying the  
792 skin cancer-fighting worthwhile frontiers: How relevant are the itraconazole/ascorbyl palmitate  
793 nanovectors? *Nanomedicine: Nanotechnology, Biology and Medicine* 43, 102561.

794 Liu, Y., Kong, M., Feng, C., Yang, K.K., Li, Y., Su, J., Cheng, X.J., Park, H.J., Chen, X.G.,  
795 2013. Biocompatibility, cellular uptake and biodistribution of the polymeric amphiphilic  
796 nanoparticles as oral drug carriers. *Colloids and Surfaces B: Biointerfaces* 103, 345-353.

797 Lu, B., Lv, X., Le, Y., 2019. Chitosan-modified PLGA nanoparticles for control-released drug  
798 delivery. *Polymers* 11, 304.

799 Łukasiewicz, S., Mikołajczyk, A., Błasiak, E., Fic, E., Dziejicka-Wasylewska, M., 2021.  
800 Polycaprolactone nanoparticles as promising candidates for nanocarriers in novel nanomedicines.  
801 *Pharmaceutics* 13, 191.

802 Manosroi, A., Chutoprapat, R., Abe, M., Manosroi, W., Manosroi, J., 2012. Transdermal  
803 absorption enhancement of rice bran bioactive compounds entrapped in niosomes. *AAPS*  
804 *PharmSciTech* 13, 323-335.

805 Nguyen, T.X., Huang, L., Liu, L., Abdalla, A.M.E., Gauthier, M., Yang, G., 2014. Chitosan-  
806 coated nano-liposomes for the oral delivery of berberine hydrochloride. *Journal of Materials*  
807 *Chemistry B* 2, 7149-7159.

808 Pandit, J., Sultana, Y., Aqil, M., 2017. Chitosan-coated PLGA nanoparticles of bevacizumab as  
809 novel drug delivery to target retina: optimization, characterization, and in vitro toxicity  
810 evaluation. *Artificial cells, nanomedicine, and biotechnology* 45, 1397-1407.

811 Patra, A., Satpathy, S., Shenoy, A.K., Bush, J.A., Kazi, M., Hussain, M.D., 2018. Formulation  
812 and evaluation of mixed polymeric micelles of quercetin for treatment of breast, ovarian, and  
813 multidrug resistant cancers. *International journal of nanomedicine* 13, 2869.

814 Quagliariello, V., Vecchione, R., Coppola, C., Di Cicco, C., De Capua, A., Piscopo, G., Paciello,  
815 R., Narciso, V., Formisano, C., Taglialatela-Scafati, O., 2018. Cardioprotective effects of

816 nanoemulsions loaded with anti-inflammatory nutraceuticals against doxorubicin-induced  
817 cardiotoxicity. *Nutrients* 10, 1304.

818 Rawal, T., Mishra, N., Jha, A., Bhatt, A., Tyagi, R.K., Panchal, S., Butani, S., 2018. Chitosan  
819 nanoparticles of gamma-oryzanol: Formulation, optimization, and in vivo evaluation of anti-  
820 hyperlipidemic activity. *Aaps Pharmscitech* 19, 1894-1907.

821 Ruktanonchai, U., Sakulkhu, U., Bejrapha, P., Opanasopit, P., Bunyapraphatsara, N.,  
822 Junyaprasert, V., Puttipipatkachorn, S., 2009. Effect of lipid types on physicochemical  
823 characteristics, stability and antioxidant activity of gamma-oryzanol-loaded lipid nanoparticles.  
824 *Journal of microencapsulation* 26, 614-626.

825 Seetapan, N., Bejrapha, P., Srinuanchai, W., Ruktanonchai, U.R., 2010. Rheological and  
826 morphological characterizations on physical stability of gamma-oryzanol-loaded solid lipid  
827 nanoparticles (SLNs). *Micron* 41, 51-58.

828 Shalaby, K.S., Soliman, M.E., Bonacucina, G., Cespi, M., Palmieri, G.F., Sammour, O.A., El  
829 Shamy, A.A., Illum, L., Casettari, L., 2016. Nanoparticles Based on Linear and Star-Shaped  
830 Poly(Ethylene Glycol)-Poly( $\epsilon$ -Caprolactone) Copolymers for the Delivery of Antitubulin Drug.  
831 *Pharmaceutical Research* 33, 2010-2024.

832 Shalaby, K.S., Soliman, M.E., Casettari, L., Bonacucina, G., Cespi, M., Palmieri, G.F.,  
833 Sammour, O.A., El Shamy, A.A., 2014. Determination of factors controlling the particle size and  
834 entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks.  
835 *International journal of nanomedicine* 9, 4953.

836 Silva, M.M., Calado, R., Marto, J., Bettencourt, A., Almeida, A.J., Gonçalves, L., 2017. Chitosan  
837 nanoparticles as a mucoadhesive drug delivery system for ocular administration. *Marine drugs*  
838 15, 370.

839 Song, X., Pang, H., Cui, W., Zhang, J., Li, J., Jia, L., 2021. Renoprotective effects of enzyme-  
840 hydrolyzed polysaccharides from *Auricularia polytricha* on adenine-induced chronic kidney  
841 diseases in mice. *Biomedicine & Pharmacotherapy* 135, 111004.

842 Tentor, F.R., de Oliveira, J.H., Scariot, D.B., Lazarin-Bidoia, D., Bonafe, E.G., Nakamura, C.V.,  
843 Venter, S.A., Monteiro, J.P., Muniz, E.C., Martins, A.F., 2017. Scaffolds based on  
844 chitosan/pectin thermosensitive hydrogels containing gold nanoparticles. *International journal of*  
845 *biological macromolecules* 102, 1186-1194.

846 Tiboni, M., Elmowafy, E., El-Derany, M.O., Benedetti, S., Campana, R., Verboni, M., Potenza,  
847 L., Palma, F., Citterio, B., Sisti, M., 2022. A combination of sugar esters and chitosan to promote  
848 in vivo wound care. *International Journal of Pharmaceutics* 616, 121508.

849 Viriyaroj, A., Ngawhirunpat, T., Sukma, M., Akkaramongkolporn, P., Ruktanonchai, U.,  
850 Opanasopit, P., 2009. Physicochemical properties and antioxidant activity of gamma-oryzanol-  
851 loaded liposome formulations for topical use. *Pharmaceutical development and technology* 14,  
852 665-671.

853 Wu, H., Huang, J., 2018. Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and  
854 prevention strategies. *Current drug metabolism* 19, 559-567.

855 Wu, J., Pan, X., Fu, H., Zheng, Y., Dai, Y., Yin, Y., Chen, Q., Hao, Q., Bao, D., Hou, D., 2017.  
856 Effect of curcumin on glycerol-induced acute kidney injury in rats. *Scientific reports* 7, 1-11.

857 Yan, L.-T., Xie, X.-M., 2013. Computational modeling and simulation of nanoparticle self-  
858 assembly in polymeric systems: Structures, properties and external field effects. *Progress in*  
859 *Polymer Science* 38, 369-405.

860 Yang, K.-M., Chiang, P.-Y., 2019. Preparation and evaluation of release formulation of  $\gamma$ -  
861 oryzanol/algae oil self-emulsified with alginate beads. *Marine Drugs* 17, 156.

862 Yun, Y., Cho, Y.W., Park, K., 2013. Nanoparticles for oral delivery: targeted nanoparticles with  
863 peptidic ligands for oral protein delivery. *Advanced drug delivery reviews* 65, 822-832.

864 Zhang, Q., Polyakov, N.E., Chistyachenko, Y.S., Khvostov, M.V., Frolova, T.S., Tolstikova,  
865 T.G., Dushkin, A.V., Su, W., 2018. Preparation of curcumin self-micelle solid dispersion with  
866 enhanced bioavailability and cytotoxic activity by mechanochemistry. *Drug Delivery* 25, 198-  
867 209.

868

869

870

871

872


873

874


875

876

877  
878




879  
880 **Fig. 1: Transmission electron microscope (TEM) images of : a) uncoated micelles (M3) and b)**  
881 **chitosan coated micelles (C-M3<sub>(0.5)</sub>) visualized under a voltage of 200 kV**  
882



883  
884 **Fig. 2: In-vitro release profiles of ORZ from uncoated micelle-core formulae (M1 and M3) and**  
885 **chitosan coated micelles (C-M1<sub>(0.5)</sub> and C-M13<sub>(0.5)</sub>) in simulated intestinal fluid at 37 °C.**

886




887

888 **Fig. 3: DSC thermograms of ORZ, DB, TB copolymers, uncoated micelles (M1 and M3) and**  
 889 **chitosan coated micelles (C-M1<sub>(0.5)</sub> and C-M13<sub>(0.5)</sub>).**

890


891



892


893

894 Fig.4: FTIR spectra of ORZ, DB, TB copolymers, uncoated micelles (M1 and M3) and the chitosan  
 895 coated micelles (C-M1<sub>(0.5)</sub> and C-M3<sub>(0.5)</sub>).  
 896



897


898 Fig 5: Percent cell viability of Vero cells after 24 h incubation with free ORZ , uncoated  
 899 micelles (M3) and chitosan coated micelles (C-M13<sub>(0.5)</sub>)



900



901 **Fig 6: Nephrotoxic indices; a) urea and b) creatinine of the different rat groups following**  
 902 **in glycerol induced AKI model. Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)**



<b>F</b>	Control (A)	AKI (B)	Free $\gamma$ Oryzanol (C)	Uncoated Micelles (D)	Chitosan coated $\gamma$ Oryzanol (E)
Congested blood vessels	0	2	2	0	0
Tubular necrosis	1	4	3	2	1
Luminal casts	0	4	2	2	1
Cystic dilatation	0	2	1	0	0


903  
 904 **Figure 7: Effects of free, chitosan coated and uncoated ORZ treatment on renal**  
 905 **histopathology and scoring in glycerol induced acute kidney injury.**

906 Photomicrographs of H&E stained sections of kidney depicting (A) Control group shows normal  
 907 histological features of renal parenchyma with apparent intact renal corpuscles (star), renal  
 908 tubular segments with almost intact tubular epithelium (arrow) as well as intact vasculatures.(B)  
 909 Glycerol induced AKI shows sever alteration of histological features than control group with more  
 910 abundant records of necrotic and hyperesophilic tubular segments losing its luminal border  
 911 integrity (black arrow) as well as moderate cystic dilatation of some tubules higher records of  
 912 intraluminal desquamated epithelial cells as well as casts were shown (red arrow) and mild  
 913 congested interstitial blood vessels (red star).(C) Free ORZ group shows diffuse records of  
 914 moderate tubular degenerative changes with many figures of vacuolar degeneration of various  
 915 tubular segments (black arrow) with occasional necrotic cells, mild focal records of intraluminal  
 916 cellular casts (red arrow) and mild congested interstitial blood vessels (red star).(D) Uncoated  
 917 micelle group shows mild protective efficacy with moderate higher records of tubular vacuolar  
 918 degenerative changes (arrow) with few focal records of tubular necrosis (star). (E) Chitosan coated  
 919 micelles group of ORZ demonstrates mild focal records of tubular degenerative changes and  
 920 nuclear pyknosis(red arrow) with abundant records of apparent intact nephronal segments (black

921 arrow) and renal corpuscles with intact vasculatures.(F) Renal damage score in different studied  
922 groups. *Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)*

923


924



925


926 **Figure 8:** Effects of free ORZ , uncoated and chitosan coated ORZ treatment on renal  
927 sirtuin -1 levels in glycerol induced acute kidney injury. Data are presented as mean  $\pm$  SEM (n  
928 = 4). Statistical Analysis was performed using one-way ANOVA followed by Tukey's test as post-hoc  
929 test. *Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)*

930




931

932 **Figure 9: Effects of free ORZ, chitosan coated and uncoated micelle treatment on renal**  
 933 **expression of antioxidant genes: (A) MnSOD, (B) UCP2 and (C) PGC-1 $\alpha$  in glycerol**  
 934 **induced acute kidney injury. Data are presented as mean  $\pm$  SEM (n = 4). Statistical**  
 935 **Analysis was performed using one-way ANOVA followed by Tukey's test as post-hoc test.**  
 936 *Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)*



937


938 **Figure 10: Effects of free ORZ, uncoated and chitosan coated ORZ treatment on renal**  
 939 **expression of autophagy genes: (A) ATG 5, (B) ATG 7, (C) ATG 12 and (D) ULK-1in**  
 940 **glycerol induced acute kidney injury. Data are presented as mean  $\pm$  SEM (n = 4). Statistical**  
 941 **Analysis was performed using one-way ANOVA followed by Tukey's test as post-hoc test.**  
 942 *Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)*



943

944 **Figure 11: Effects of free ORZ, uncoated and chitosan coated  $\gamma$  oryzanol treatment on**  
 945 **renal inflammatory markers: (A) IL-6, (B) IL-1 $\beta$  and (C) TGF- $\beta$  in glycerol induced acute**  
 946 **kidney injury. Data are presented as mean  $\pm$  SEM (n = 4). Statistical Analysis was**  
 947 **performed using one-way ANOVA followed by Tukey's test as post-hoc test.**

948 *Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)*



949

950 **Figure 12: Effects of free ORZ, uncoated and chitosan coated ORZ treatment on renal**  
 951 **expression of apoptosis genes: (A) BAX, (B) Bcl-2, (C) BAX/Bcl2 ratio, (D) P53 and (E)**  
 952 **PUMA in glycerol induced acute kidney injury. Data are presented as mean  $\pm$  SEM (n = 4).**  
 953 **Statistical Analysis was performed using one-way ANOVA followed by Tukey's test as**  
 954 **post-hoc test. Uncoated micelles (M3) and Corresponding chitosan coated micelles (C-M3<sub>(0.5)</sub>)**

955

956

957

958

959

960

961

962

963

964 **Table 1: Fabrication,colloidalparameters, drug loading levels and encapsulation efficiencies**  
965 **of ORZ micelle-core (each value represents the mean±SD, *n* = 3).**

<b>Formulation</b>	<b>Copolymer type</b>	<b>Polymer ratio to ORZ</b>	<b>PS (nm)</b>	<b>PDI</b>	<b>ZP (mV)</b>	<b>DL (%)</b>	<b>EE (%)</b>
<b>M1</b>	DB	5 to 1	105.4 ±0.87	0.255 ±0.012	-12.6 ±2.1	13.45 ±0.99	67.28 ± 4.98
<b>M2</b>	DB	10 to 1	98.88 ±0.461	0.219 ±0.003	-14.4 ±0.643	7.93 ±0.17	79.34 ±1.77
<b>M3</b>	TB	5 to 1	117.8 ±0.945	0.249 ±0.017	-27.8 ±1.76	17.00 ±0.63	85.03 ±3.17
<b>M4</b>	TB	10 to 1	97.9 ±11.22	0.381 ±0.077	-29.2 ±2.54	9.38 ±0.21	93.87 ±2.10

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981 **Table 2: Sequences of primers pairs used for gene expression analysis.**

982

<b>Gene symbol</b>	<b>Primer sequence</b>
MnSOD F:	5'-GTGCAGGTAAGTGGCAGGG -3'
MnSOD R:	5'-TCGTGGTACTTCTCCTCGGT -3'
UCP2 F:	5'-CGTCTGCACTCCTGTGTTCT-3'
UCP2 R:	5'-TGTTGAGTGGGGCATTGTGT -3'
PGC-1 $\alpha$ F:	5'-AGCCTCTTTGCCAGATCTT-3'
PGC-1 $\alpha$ R:	5'-GCAATCCGTCTTCATCCACC-3'
ATG 5 F:	5'-TGGACCATCAACCGGAAACT-3'
ATG 5 R:	5'-AAGGGTATGCAGCTGTCCAT-3'
ATG 7 F:	5'-CTGCTCTCGAAAACCCCATG-3'
ATG 7 R:	5'-AAGAAGTATGGCAGGGCTGT-3'
ATG 12 F:	5'-CTCTCCCCAGAAACAGCCAT-3'
ATG 12 R:	5'-TCGATGAGTGCTTGGACAGT-3'
ULK1 F:	5'-GTTGCTGACTCCAAGCCAAA-3'
ULK1 R:	5'-ATCTTGGAGGACGAAAGCCA-3'
Bax F:	5'-GATCAGCTCGGGCACTTTA-3'
Bax R:	5'-TGTTTGCTGATGGCAA CTTC-3'
Bcl-2 F:	5'-AGGAT TGTGG CCTTC TTTGA GT-3'
Bcl-2 R:	5'-GCCG GTTC AGG TACT CAGT CAT-3'
TP53 F:	5'-CAGCTTTGAGGTTCTGTGTTTGT-3'
TP53 R:	5'-ATGCTCTTCTTTTTTTCGGAAA-3'
PUMA F:	5'-GTG TGG AGG AGGAGG AGT GG-3'
PUMA R:	5'-TCG GTG TCG ATG TTG CTC TT-3'
$\beta$ -actin F:	5'- TGTCACCAACTGGGACGATA-3'
$\beta$ -actin R:	5'- GGGGTGTTGAAGGTCTCAA-3'



983 MnSOD, manganese superoxide dismutase; UCP2, uncoupling protein-2; PGC-1 $\alpha$ , Peroxisome  
 984 proliferator-activated receptor gamma coactivator 1-alpha; ATG, Autophagy-related genes;  
 985 ULK1, unc-51 like autophagy activating kinase 1; Bax, Bcl-2-associated X protein; Bcl-2, B-cell  
 986 lymphoma2; Tp53, tumor protein 53; PUMA, p53 upregulated modulator of apoptosis;  $\beta$ -actin,  
 987 beta actin.

988

989

990 **Table 3: Fabrication and colloidal parameters of ORZ chito-micelles (each value represents**  
 991 **the mean $\pm$ SD,  $n = 3$ ).**

992

<b>Formulation</b>	<b>CS concentration</b>	<b>PS (nm)</b>	<b>PDI</b>	<b>ZP (mV)</b>
<b>M1</b>	-	105.4 $\pm$ 0.87	0.255 $\pm$ 0.012	-12.6 $\pm$ 2.1
<b>C-M1<sub>(0.25)</sub></b>	0.25	136.7 $\pm$ 7.605	0.393 $\pm$ 0.021	23.2 $\pm$ 1.56
<b>C-M1<sub>(0.5)</sub></b>	0.5	178.5 $\pm$ 4.424	0.458 $\pm$ 0.033	31.5 $\pm$ 2.95
<b>C-M1<sub>(1)</sub></b>	1	411 $\pm$ 12.75	0.61 $\pm$ 0.153	41.8 $\pm$ 1.99
<b>M3</b>	-	117.8 $\pm$ 0.945	0.249 $\pm$ 0.017	-27.8 $\pm$ 1.76
<b>C-M3<sub>(0.25)</sub></b>	0.25	156.9 $\pm$ 1.47	0.41 $\pm$ 0.063	24.9 $\pm$ 2.24
<b>C-M3<sub>(0.5)</sub></b>	0.5	194.8 $\pm$ 1.185	0.428 $\pm$ 0.003	37.4 $\pm$ 0.781
<b>C-M3<sub>(1)</sub></b>	1	480 $\pm$ 10.68	0.927 $\pm$ 0.023	44.1 $\pm$ 0.850

993

994

995

996

997

998

999

1000

1001

1002 **Table 4: Stability of Optimized ORZ-loaded chito-micelles after 1-month and 3-month**  
1003 **storage periods at room temperature and 4°C**

Parameter	Fresh C-M3 <sub>(0.5)</sub>	Stored C-M3 <sub>(0.5)</sub> at 4°C		
		7 days	14 days	28 days
PS (nm)	194.8±1.185	190.5±7.65	210.9±5.26	213.9±9.27
PDI	0.42±0.003	0.48±0.01	0.42±0.009	0.43±0.03
ZP (mV)	37.4±0.781	37.8±1.2	36±2.32	33.2±0.89

1004

1005